Matthew Biegler
Stock Analyst at Oppenheimer
(1.08)
# 3,690
Out of 4,944 analysts
78
Total ratings
30.43%
Success rate
-13.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Reiterates: Outperform | $32 → $30 | $10.02 | +199.40% | 2 | Jul 31, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $1.86 | +276.34% | 1 | Jul 31, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $10 → $9 | $1.25 | +620.00% | 2 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.03 | +773.79% | 2 | May 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $25 → $22 | $5.31 | +314.31% | 6 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $9.52 | +26.05% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $1.66 | +381.93% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $6.80 | +562.25% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $120.02 | -4.18% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $23.62 | +124.43% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $10.60 | +211.32% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.41 | +1,318.44% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.35 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $11.26 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.54 | +114.07% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.40 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $0.94 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $6.14 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.96 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.06 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $8.71 | +4,033.18% | 1 | Nov 30, 2022 |
Nurix Therapeutics
Jul 31, 2025
Reiterates: Outperform
Price Target: $32 → $30
Current: $10.02
Upside: +199.40%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $1.86
Upside: +276.34%
Acrivon Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.25
Upside: +620.00%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.03
Upside: +773.79%
Olema Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $5.31
Upside: +314.31%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $9.52
Upside: +26.05%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.66
Upside: +381.93%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $6.80
Upside: +562.25%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $120.02
Upside: -4.18%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $23.62
Upside: +124.43%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $10.60
Upside: +211.32%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.41
Upside: +1,318.44%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.35
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $11.26
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $6.54
Upside: +114.07%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.40
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $0.94
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $6.14
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.96
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.06
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $8.71
Upside: +4,033.18%